Learn all about BioChromatographix International at the BioProcessing Network 2026 Sydney Conference
- Jul 27
- 2 min read
Updated: Jul 28
Join us at the
BioProcessing Network 2026 Conference
15th-17th September
Royal Randwick Racecourse - Australian Turf Club Alison Rd, Randwick NSW 2031 Sydney, Australia Winx Galleries (Level 1, Winx Stand)
MetaGene is proud to represent Singapore manufacturer BioChromatographix International (BCI).
BioChromatographix International (BCI) develops and manufactures Next-Generation Monolithic Chromatography media for the downstream purification of Cell and Gene Therapy.
BCI was founded in 2024 to solve a real problem in downstream processing. The team includes biopharma manufacturing veterans and scientific advisors with decades of bioprocess experience. In 2026, the company was recognised at the IMAPAC Asia Pacific Biopharma Excellence Awards for innovation in downstream processing.
Come along to the BioProcessing Network 2026 Conference, 15th-17th September, to learn all about BioChromatographix International (BCI) !
The Problem, the Solution and Why It Matters
By Scott Wheelwright, Chairman, CTO & Co-Founder, BioChromatographix International (BCI)
The Problem: Traditional bead-based chromatography is diffusion-limited. While effective for proteins and small molecules, it struggles with large biomolecules — viruses, plasmids, mRNA, exosomes and others that cannot access most of the pore volume. This makes purification slow, inefficient, and costly.
The Solution: At BCI, we developed the AXISFLOW™ platform: a monolithic chromatography medium with interconnected microchannels. Instead of diffusion, liquid moves through these channels by convection, enabling rapid and efficient purification even for the largest biomolecules. In essence, we remove the diffusion bottleneck — delivering purification that is faster, more scalable, and more cost- effective.
Why This Matters: The promise of advanced therapies is extraordinary, but their cost of goods remains a critical barrier to patient access. If purification cannot keep pace, many therapies will remain out of reach. AXISFLOW™ directly tackles this bottleneck — helping innovators cut costs, shorten timelines, and bring next-generation treatments to the people who need them most.
Headquartered and manufactured in Singapore
(1) Scanning electron micro graph of AXISFLOW™ monolith structure used for purification of plasmids.
AXISFLOW™
Shaping the Future of Purification
BCI's flagship AXISFLOW™ platform is a portfolio of monolithic chromatography columns for the purification of pDNA, AAV, lentivirus, mRNA, exosomes, and virus-like particles. The inverted-flow architecture enables convective, flow-independent mass transfer.
AXISFLOW™ QA is a strong anion exchange monolith for pDNA purification. The inverted-flow architecture moves product by convection, so recovery stays high and backpressure stays low, even at fast flow rates.
Performance is peer-reviewed.
AXISFLOW™ ensures unmatched consistency, higher binding capacity, reduced complexity, and breakthrough performance for biomanufacturing workflows.
Driven by innovation and inspired by efficiency, BCI empowers scientists and manufacturers to achieve faster, more reliable and cost-effective biomolecule purification.
Key Features
>90% supercoiled pDNA recovery across plasmid sizes
Yield independent of flow rate (1–20 CV/min, peer-reviewed)
~3× lower pressure drop than established monoliths
Peer-reviewed: Separation and Purification Technology (2026)
(1) Figure Source: Scott Wheelwright, Eric Soon, Natalie Wong, Sze Yi Lau, Alois Jungbauer, AXISFLOW™ monoliths with inverted flow morphology and high void volume enable efficient large plasmid purification, Separation and Purification Technology, Volume 394, Part 3, 2026.